Joseph A. Fraietta, PhD (left) and J. Joseph Melenhorst, PhD (right)
PHILADELPHIA – The doctors who have spent years studying the case call it “a series of fortunate events.” What began as a remarkable response to chimeric antigen receptor (CAR) T cell therapy is now providing evidence about the human genome and immune response that could help turn gene therapy non-responders into responders. Researchers at the University of Pennsylvania’s Abramson Cancer Center say a patient treated for chronic lymphocytic leukemia (CLL) in 2013 went into remission because of a single CAR T cell and the cells it produced as it multiplied, and has stayed cancer free in the five years since, with CAR T cells still present in his immune system. The findings, published today in Nature, show the response is tied to where the CAR gene inserted itself into the patient’s T cell DNA, a key factor that may help improve response rates to the therapy.
CLL is a type of cancer that starts in cells that become certain white blood cells in the bone marrow, and then move into the blood and lymph nodes. These cancer cells reproduce too quickly and crowd out other cells in the bone marrow. They also don’t mature properly and thus don’t fight off infection as well as they should. The American Cancer Society estimates there will be about 21,000 new CLL cases in 2018 and around 4,500 deaths from the disease.
Many of these patients will undergo a bone marrow transplant, but a potential additional treatment is CAR T cell therapy, which involves collecting patients’ own immune T cells, reprogramming them to recognize and kill cancer, and then infusing them back into patients’ bodies. The approach is approved by the U.S. Food and Drug Administration for certain acute lymphoblastic leukemia patients as well as some non-Hodgkin’s lymphoma patients, but is not currently approved for treatment of CLL.
Patients typically receive three consecutive infusions with increasing doses – 10 percent, 30 percent, and 60 percent – to control for cytokine release syndrome (CRS). CRS is a common toxicity associated with CAR T therapy and includes varying degrees of flu-like symptoms, with fevers, nausea, and muscle pain, and can require ICU-level care. The patient in this report received the first two infusions of 10 and 30 percent, but did not initially respond.
“It wasn’t until day 50 that the patient experienced CRS, which indicated the CAR T cells were active and may be having an anti-tumor effect,” said the study’s senior author J. Joseph Melenhorst, PhD, an associate professor of Pathology and Laboratory Medicine in Penn’s Perelman School of Medicine and a member of Penn’s Center for Cellular Immunotherapies.
Imaging showed the tumor had gotten smaller, so doctors decided to infuse the patient with the final 60 percent. The patient went into remission and has stayed there for five years and counting.
“It’s the outcome we’re always hoping for, but we know we can learn so much from every single patient no matter what. We brought this from the bedside back to the bench to understand as much as we could about what happened and why,” said study co-senior author Carl June, MD, the Richard W. Vague Professor in Immunotherapy, a professor of Pathology and Laboratory Medicine, and director of the Center for Cellular Immunotherapies.
“The first thing we found was that we could trace the lineage of the patient’s CAR T cells back to a single, original cell,” said the study’s lead author Joseph A. Fraietta, PhD, an assistant professor of Pathology and Laboratory Medicine and a member of the Center for Cellular Immunotherapies. “It’s a truly remarkable finding, and essentially tells us the minimum dose needed for CAR T cells to do their job is one.”
This patient’s CAR T cells were engineered to seek out a protein on leukemia cells known as CD19. In this strategy, the genetic code for the CAR that recognizes CD19 protein is randomly inserted into the patient’s DNA by a genetically-modified virus.
In this particular case, researchers found the CAR sequence inserted into a gene called TET2 that normally regulates blood cell formation and keeps growth of these cells in check. Once the TET2 gene was disrupted, the single CAR T cell expanded massively and wiped out this patient’s leukemia.
“Killer T cells that normally fight off infection generally can’t beat cancer alone because they’re older, past their prime, and often outnumbered,” Fraietta said. “However, younger cells make the difference because of their ability to expand massively into an army of effectors. In this case, they got a chance to do their work because TET2 was inhibited which affected epigenetic pathways to drive this response.”
“This analysis required a huge collaboration between immunologists, cell biologists, T cell experts, cancer biologists, and clinicians,” Melenhorst said. “Fortunately, we have all of that expertise here, and it proved invaluable.”
Other co-authors of the study include Frederic Bushman, PhD, the William Maul Measey Professor and chair of Microbiology, Shelley Berger, PhD, the Daniel S. Och University Professor and a Penn Integrates Knowledge Professor with appointments in the Perelman School of Medicine’s department of Cell and Developmental Biology and the School of Arts and Sciences department of Biology, and David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center.
In 2012, Penn and Novartis entered into a global collaboration to further research, develop and commercialize Kymriah, formerly known as CTL019, and other CAR T cell therapies for the treatment of cancers. In August 2017, the U.S. Food and Drug Administration approved Kymriah for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or relapsed. In May of 2018, the approval was expanded to include the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) – the most common form of non-Hodgkin’s lymphoma – as well as high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
This work was supported by funding from National Cancer Institute (T32CA009140, P01CA214278, AI104400, AI 082020, AI045008, AI117950), the National Institute of Allergy and Infectious Diseases (K08AI101008), the National Institute of General Medical Sciences (R01GM118501, R01CA165206), a Stand Up to Cancer Phillip A. Sharp Innovation in Collaboration Award, and Novartis.
Editor’s note: The University of Pennsylvania has licensed technologies involved in these trials to Novartis. Some of the scientists involved in these trials are inventors of these technologies. As a result of the licensing relationship with Novartis, the University of Pennsylvania receives significant financial benefit, and these inventers have benefitted financially and/or may benefit financially in the future.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.